BioTheranostics gets OK to distribute breast cancer Dx in N.Y.

07/17/2014 | GenomeWeb Daily News (free registration)

BioTheranostics has received the go-ahead to distribute its Breast Cancer Index in New York. The molecular diagnostic assay measures a patient's risk of recurrent estrogen receptor-positive breast cancer and determines whether extended endocrine treatment will benefit the patient.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC